15 Apr 2020 --- Eicosapentaenoic acid free fatty acid (EPA-FFA) and extract from Artemisia annua (also known as sweet wormwood) are being investigated in the fight against COVID-19. EPAspire, the drug candidate of KD Pharma and its partner, SLA Pharma, is soon entering clinical trials as a promising candidate to treat patients with symptoms of the novel coronavirus infection. Meanwhile, ArtemiLife is collaborating with the Max Planck Institute of Colloids and Interfaces to test Artemisia annua plant extract and artemisinin (an anti-malarial drug) derivatives in laboratory cell studies.
